Skip to content

Erasca, Inc. ERAS Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding

Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$0
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$0
GRAIL, Inc. logo
GRAIL, Inc.GRAL
$0
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Exelixis logo
ExelixisEXEL
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Erasca, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Erasca, Inc.'s preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
Erasca, Inc. (ERAS) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q4 2025.
What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
This represents the par value of preferred shares issued by the company, which carry specific rights and preferences over common stock, such as priority in dividend payments or liquidation. Preferred stock is a form of hybrid capital that sits between debt and common equity. If no shares are issued, this value remains at zero.